Reviewing InflaRx N.V. (IFRX)’s and Neptune Wellness Solutions Inc. (NASDAQ:NEPT)’s results

We are contrasting InflaRx N.V. (NASDAQ:IFRX) and Neptune Wellness Solutions Inc. (NASDAQ:NEPT) on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InflaRx N.V. N/A 0.00 N/A -1.42 0.00
Neptune Wellness Solutions Inc. N/A 0.00 N/A -0.07 0.00

Demonstrates InflaRx N.V. and Neptune Wellness Solutions Inc. earnings per share, top-line revenue and valuation.


Table 2 provides the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
InflaRx N.V. 0.00% -22.7% -21.9%
Neptune Wellness Solutions Inc. 0.00% 0% 0%

Institutional and Insider Ownership

InflaRx N.V. and Neptune Wellness Solutions Inc. has shares owned by institutional investors as follows: 58.8% and 17.71%. Competitively, Neptune Wellness Solutions Inc. has 23.66% of it’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
InflaRx N.V. 0.99% -4.81% -11.65% -15.66% 63.49% 40.86%
Neptune Wellness Solutions Inc. -8.44% -24.68% -22.89% 17.2% 104.9% 24.15%

For the past year InflaRx N.V.’s stock price has bigger growth than Neptune Wellness Solutions Inc.


On 3 of the 5 factors Neptune Wellness Solutions Inc. beats InflaRx N.V.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.

Neptune Technologies & Bioressources Inc., a nutrition products company, focuses on providing nutrition solutions, including specialty ingredients and consumer brands. The company develops solutions available in various delivery forms. It also offers various specialty ingredients, including premium krill oil and other marine oils, as well as seed oils. The company sells its premium krill oil under the OCEANO3 brand directly to consumers through in Canada and the United States. In addition, Neptune Technologies & Bioressources Inc. is pursuing opportunities in the prescription drug markets, through its subsidiary, Acasti Pharma Inc., that focuses on the research, development, and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia. The company was founded in 1925 and is headquartered in Laval, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.